RxDoctor Payments Data

Ogugua Obi, MD

Pulmonary Disease · Greenville, NCNPI 1477685360

Payments from drug & device makers

$61,775in general payments, 2019–2025

Across 17 payments — averaging $3633.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$45K
  • CSL Behring$16K
  • Mallinckrodt Enterprises LLC$90
  • GSK$49
  • ANI Pharmaceuticals, Inc.$27
  • Nxstage Medical, Inc.$21
  • plus $46 from 3 others

What the payments were for

  • Consulting fees$10,89567%
  • Travel & lodging$5,02231%
  • Food & beverage$3882%
  • Education$140%

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$61,775 in reported general payments places this provider in the 80th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$64,996
Medicare patients
186
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate44$566,995
RemicadeInfliximab52$378,578
InflectraInfliximab-Dyyb23$119,232
Dupixent PenDupilumab17$73,432
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$42,632
RenflexisInfliximab-Abda12$36,681
Breo ElliptaFluticasone/Vilanterol66$27,472
Spiriva RespimatTiotropium Bromide38$20,003
SymbicortBudesonide/Formoterol Fumarate71$19,174
Incruse ElliptaUmeclidinium Bromide39$14,789
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$6,399
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$3,778
Mycophenolate Mofetil17$3,681
Albuterol Sulfate HfaAlbuterol Sulfate91$3,095
MethotrexateMethotrexate Sodium149$2,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$14$593,39796 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$49$84,893162 claims
AstraZenecaSymbicort$17$19,17471 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →